New Two-Pronged attack tested for Tough-to-Treat prostate cancer

NCT ID NCT07082920

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing a combination of two new, experimental drugs for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The main goals are to find a safe and effective dose for the drug pair and to see how well patients tolerate the treatment. The study will enroll about 140 participants.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Columbia University Medical Center
RECRUITING

New York, New York, 10032, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Fred Hutchinson Cancer Center
RECRUITING

Seattle, Washington, 98109, United States
Royal Marsden Hospital (Sutton)
RECRUITING

Sutton, SM2 5PT, United Kingdom
The Christie Nhs Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
University Hospitals Cleveland Medical Center
RECRUITING

Cleveland, Ohio, 44106, United States

Conditions

Explore the condition pages connected to this study.

PROSTATIC NEOPLASMS